文献速递前列腺癌

前列腺影像报告和数据系统第2版对临床显著性前列腺癌检测的阳性预测值:系统综述与荟萃分析

Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2020-12-25

结果显示可疑mpMRI对csPCa的PPV为40%(95%CI 36-43%),PI-RADS 3、4、5的PPV分别为13%、40%、69%(p<0.001),且PPV随疾病患病率增加而升高。

要点

  • 可疑mpMRI对csPCa的PPV为40%,但研究间异质性大(I2=94%)。
  • PI-RADS 3、4、5的csPCa PPV分别为13%、40%、69%(p<0.001)。
  • 初诊与既往阴性活检组的csPCa PPV分别为42%与32%(p=0.005)。

核心结论

  • mpMRI的PPV强烈依赖疾病患病率,主要影响因素为PI-RADS第2版评分和既往活检状态。
  • PI-RADS 3病灶的PPV显著较低,PI-RADS 4和5病灶的PPV仍不理想。
  • 系统穿刺对csPCa的附加价值相对较低,但可改善患者风险评估和分期。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Cochrane图书馆Central、EMBASE、MEDLINE和Scopus数据库2015年1月至2020年6月文献。

主要发现

  • 可疑mpMRI对csPCa的PPV为40%(95%CI 36-43%),异质性大(I2=94%,p<0.01)。
  • PI-RADS 3、4、5的csPCa PPV分别为13%、40%、69%(p<0.001)。
  • TBx在PI-RADS 3、4、5病灶中分别漏诊6%、6%、5%的csPCa。
  • 初诊活检组和既往阴性活检组的csPCa PPV分别为42%和32%(p=0.005)。
  • 研究设计、TBx技术和采样芯数不影响PPV。

关键数值与推荐

  • PI-RADS 3病灶的csPCa PPV为13%,PI-RADS 4为40%,PI-RADS 5为69%(p<0.001)。
  • 初诊活检组csPCa PPV为42%,既往阴性活检组为32%(p=0.005)。
  • TBx在PI-RADS 3、4、5病灶中漏诊csPCa的比例分别为6%、6%、5%。

临床怎么用

  • 对PI-RADS 3病灶行靶向穿刺应谨慎,需结合个体风险评估确认csPCa存在。
  • 高度可疑病灶的PPV不足以省略系统前列腺采样。
  • 临床决策应考虑疾病患病率和既往活检状态对PPV的影响。

局限性

  • 研究间异质性大(I2=94%),可能影响结果稳定性。
  • 接受各作者对csPCa的定义和mpMRI阳性的PI-RADS阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The variability of the positive predictive value (PPV) represents a significant factor affecting the diagnostic performance of multiparametric magnetic resonance imaging (mpMRI). OBJECTIVE: To analyze published studies reporting mpMRI PPV and the reasons behind the variability of clinically significant prostate cancer (csPCa) detection rates on targeted biopsies (TBx) according to Prostate Imaging Reporting and Data System (PI-RADS) version 2 categories. EVIDENCE ACQUISITION: A search of PubMed, Cochrane library's Central, EMBASE, MEDLINE, and Scopus databases, from January 2015 to June 2020, was conducted. The primary and secondary outcomes were to evaluate the PPV of PI-RADS version 2 in detecting csPCa and any prostate cancer (PCa), respectively. Individual authors' definitions for csPCa and PI-RADS thresholds for positive mpMRI were accepted. Detection rates, used as a surrogate of PPV, were pooled using random-effect models. Preplanned subgroup analyses tested PPV after stratification for PI-RADS scores, previous biopsy status, TBx technique, and number of sampled cores. PPV variation over cancer prevalence was evaluated. EVIDENCE SYNTHESIS: Fifty-six studies, with a total of 16 537 participants, were included in the quantitative synthesis. The PPV of suspicious mpMRI for csPCa was 40% (95% confidence interval 36-43%), with large heterogeneity between studies (I2 94%, p < 0.01). PPV increased according to PCa prevalence. In subgroup analyses, PPVs for csPCa were 13%, 40%, and 69% for, respectively, PI-RADS 3, 4, and 5 (p < 0.001). TBx missed 6%, 6%, and 5% of csPCa in PI-RADS 3, 4, and 5 lesions, respectively. In biopsy-naïve and prior negative biopsy groups, PPVs for csPCa were 42% and 32%, respectively (p = 0.005). Study design, TBx technique, and number of sampled cores did not affect PPV. CONCLUSIONS: Our meta-analysis underlines that the PPV of mpMRI is strongly dependent on the disease prevalence, and that the main factors affecting PPV are PI-RADS version 2 scores and prior biopsy status. A substantially low PPV for PI-RADS 3 lesions was reported, while it was still suboptimal in PI-RADS 4 and 5 lesions. Lastly, even if the added value of a systematic biopsy for csPCa is relatively low, this rate can improve patient risk assessment and staging. PATIENT SUMMARY: Targeted biopsy of Prostate Imaging Reporting and Data System 3 lesions should be considered carefully in light of additional individual risk assessment corroborating the presence of clinically significant prostate cancer. On the contrary, the positive predictive value of highly suspicious lesions is not high enough to omit systematic prostate sampling.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Mazzone E, Stabile A, Pellegrino F, et al. Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020. PMID: 33358543. doi:10.1016/j.euo.2020.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。